Unicycive Therapeutics Q2 net loss narrows on warrant liability change

Unicycive Therapeutics

12/08/2026 12:31

Overview
US kidney disease biotech's Q2 net loss narrowed from prior year
Net loss decline attributed to change in fair value of warrant liability
Company expects to resubmit NDA for oxylanthanum carbonate after FDA facility inspection

Outlook
Unicycive plans to resubmit NDA for OLC after successful FDA inspection of manufacturing vendor
Company continues commercial readiness initiatives ahead of potential OLC launch
Unicycive aims to expand market awareness for OLC while awaiting regulatory progress

Result Drivers
WARRANT LIABILITY - Decreased net loss attributed primarily to change in fair value of warrant liability
OPERATING EXPENSES - Higher R&D and G&A expenses driven by increased non-cash stock-based compensation and commercial launch preparation

Company press release: ID:nGNXb4whq1

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.06
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Unicycive Therapeutics Inc is $30.00, about 500% above its August 11 closing price of $5.00
The stock recently traded at 2 times the next 12-month earnings vs. a P/E of 2 three months ago

Reuters Recommended Reads
Aug 10 - Scynexis Q2 swings to profit on warrant adjustment; advances drug studies
Aug 11 - Achieve Life Sciences Q2 loss widens on warrant liabilities
Aug 10 - Cell therapy developer ProKidney's Q2 operating loss widens as trial costs rise

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)